List view / Grid view
Biologics
article
Bringing native analysis into the fast-moving world of biologics
For the past thirty years, native mass spectrometry has grown in both scope and reach in labs across the globe to encompass larger and more challenging molecular complexes. However, up until now, the throughput of these techniques has been slow and manual. Christopher Nortcliffe discusses ways that native analysis is…
article
Network-driven drug discovery
Target-driven drug discovery, in which the starting point is a specific protein target hypothesised to play an important role in disease, has been the dominant paradigm for the last few decades. However, phenotypic-driven drug discovery, which does not rely on a specific target hypothesis, is starting to regain traction for…
news
PD-L1 assay specifically selects ideal patients for cancer treatment
An assay assessing the level of programmed death ligand 1 (PD-L1) could help to determine the method of treatment for lung cancer patients...
news
Neurofilament light chains detect Alzheimer’s damage before symptoms
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer's disease...
news
Nanoscale ‘tweezers’ for individual cell biopsies
Researchers have developed nanoscale 'tweezers' used to investigate single living cells, which could help to identify why healthy cells become diseased...
whitepaper
Application note: Integrated biologics – Enabling high-throughput drug discovery at Amgen with Thermo Fisher™ Platform for Science™ Software
Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.
news
Freeze-dried vaccine may help eradicate polio
Researchers have developed a polio vaccine that doesn't require refrigeration, meaning it could someday be used all over the world...
webinar
High throughput screening for deep mining of antibody repertoires, Dr. Stefan Moese, Novartis, Switzerland
9 November 2018 | By Beckman Coulter
In this webinar you learn about a high throughput screening approach for mining of antibody repertoires in the context of biologics drug discovery.
news
Disrupting quinolones to prevent antibiotic resistance
Disrupting the communication between bacteria and quinolone signalling can inhibit the the production of toxins and virulence factors...
news
Heat-resistant enzymes for cost-effective drugs
The mechanisms and actions of heat-resistant enzymes are being investigated to aid better, more cost-effective drug design...
news
The European Antibody Congress is returning to the city of Basel
The European Antibody Congress is returning to the city of Basel for its 14th year on the 29-31 October 2018, and here is everything you need to know about our biggest event yet...
news
TLR5 protein holds potential for new Alzheimer’s biotherapy
Researchers at the University of Florida have discovered that a modified version of an important immune cell protein, TLR5, could be used to treat Alzheimer's disease.
news
Monoclonal antibodies produced by new cell lines hope to improve drugs
Many biopharmaceutical companies look to produce biosimilars soon, since the patents on the original mAb expire over the next few years...
news
Hunger hormones offer promising avenue for addiction treatment
Hormones that signal the body's state of hunger and fullness could be the key to new treatments for drug and alcohol addiction...